Pharmaniaga Berhad (KLSE: PHARMA)
Malaysia
· Delayed Price · Currency is MYR 0.380
-0.005 (-1.30%)
At close: Oct 11, 2024
Pharmaniaga Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 3,479 | 3,404 | 3,481 | 4,815 | 2,725 | 2,821 | Upgrade
|
| Revenue Growth (YoY) | -0.24% | -2.20% | -27.71% | 76.69% | -3.38% | 18.26% | Upgrade
|
| Cost of Revenue | 3,155 | 3,097 | 3,138 | 4,185 | 2,430 | 2,479 | Upgrade
|
| Gross Profit | 323.56 | 307.82 | 342.72 | 630.02 | 295.2 | 341.3 | Upgrade
|
| Selling, General & Admin | 283.2 | 299.58 | 292.6 | 301.56 | 207.03 | 236.26 | Upgrade
|
| Operating Expenses | 311.89 | 328.27 | 314.72 | 322.64 | 227.61 | 248.23 | Upgrade
|
| Operating Income | 11.67 | -20.45 | 28 | 307.37 | 67.59 | 93.08 | Upgrade
|
| Interest Expense | -68.06 | -61.84 | -40.04 | -33.32 | -33.7 | -40.26 | Upgrade
|
| Interest & Investment Income | 1.64 | 1.48 | 0.91 | 1.52 | 0.63 | 1.39 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.13 | 1.13 | 0.04 | 0.93 | 0.41 | 0.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.44 | 0.66 | 3.03 | 0.51 | 0.87 | 0.72 | Upgrade
|
| EBT Excluding Unusual Items | -52.18 | -79.03 | -8.06 | 277 | 35.79 | 55.4 | Upgrade
|
| Impairment of Goodwill | - | - | -50.27 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.86 | 0.86 | 0.05 | 0.07 | - | 0.05 | Upgrade
|
| Asset Writedown | - | - | -552.31 | - | - | -247.32 | Upgrade
|
| Pretax Income | -51.32 | -78.16 | -610.59 | 277.08 | 35.79 | -191.87 | Upgrade
|
| Income Tax Expense | 2.49 | 0.58 | 17.07 | 104.87 | 9.52 | -42.42 | Upgrade
|
| Earnings From Continuing Operations | -53.81 | -78.74 | -627.65 | 172.21 | 26.27 | -149.45 | Upgrade
|
| Minority Interest in Earnings | -2.52 | -1.42 | -2.27 | -0.06 | 1.22 | 0.23 | Upgrade
|
| Net Income | -56.33 | -80.16 | -629.92 | 172.15 | 27.49 | -149.22 | Upgrade
|
| Net Income to Common | -56.33 | -80.16 | -629.92 | 172.15 | 27.49 | -149.22 | Upgrade
|
| Net Income Growth | - | - | - | 526.25% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,433 | 1,368 | 1,310 | 1,309 | 1,307 | 1,305 | Upgrade
|
| Shares Outstanding (Diluted) | 1,433 | 1,368 | 1,310 | 1,309 | 1,309 | 1,305 | Upgrade
|
| Shares Change (YoY) | 9.39% | 4.40% | 0.05% | 0.04% | 0.33% | 0.05% | Upgrade
|
| EPS (Basic) | -0.04 | -0.06 | -0.48 | 0.13 | 0.02 | -0.11 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.06 | -0.48 | 0.13 | 0.02 | -0.11 | Upgrade
|
| EPS Growth | - | - | - | 526.09% | - | - | Upgrade
|
| Free Cash Flow | -110.81 | -3.72 | -201.6 | -94.44 | -34.96 | 169.39 | Upgrade
|
| Free Cash Flow Per Share | -0.08 | -0.00 | -0.15 | -0.07 | -0.03 | 0.13 | Upgrade
|
| Dividend Per Share | - | - | 0.019 | 0.093 | 0.022 | 0.017 | Upgrade
|
| Dividend Growth | - | - | -79.57% | 322.73% | 29.41% | -46.88% | Upgrade
|
| Gross Margin | 9.30% | 9.04% | 9.85% | 13.08% | 10.83% | 12.10% | Upgrade
|
| Operating Margin | 0.34% | -0.60% | 0.80% | 6.38% | 2.48% | 3.30% | Upgrade
|
| Profit Margin | -1.62% | -2.35% | -18.10% | 3.58% | 1.01% | -5.29% | Upgrade
|
| Free Cash Flow Margin | -3.19% | -0.11% | -5.79% | -1.96% | -1.28% | 6.01% | Upgrade
|
| EBITDA | 38.19 | 7.35 | 55.62 | 335.28 | 94.43 | 124.2 | Upgrade
|
| EBITDA Margin | 1.10% | 0.22% | 1.60% | 6.96% | 3.47% | 4.40% | Upgrade
|
| D&A For EBITDA | 26.51 | 27.79 | 27.62 | 27.9 | 26.85 | 31.12 | Upgrade
|
| EBIT | 11.67 | -20.45 | 28 | 307.37 | 67.59 | 93.08 | Upgrade
|
| EBIT Margin | 0.34% | -0.60% | 0.80% | 6.38% | 2.48% | 3.30% | Upgrade
|
| Effective Tax Rate | - | - | - | 37.85% | 26.61% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.